When Johnson & Johnson (NYSE:JNJ) reported earnings yesterday, Olysio was the big headline -- the drug's $831 million in quarterly sales rocked Wall Street estimates and helped lead the dividend aristocrat to a surprisingly strong quarterly result.
But it wasn't just Olysio that drove growth. This 'sleepy' business segment turned in 6% worldwide growth at constant currency (excluding the impact of divestitures). And in one sector, growth was 17% worldwide (and nearly 25% in the U.S.). And management has targeted this segment for further growth, with CEO Alex Gorsky saying that J&J is going to "stay very active" in looking for acquisitions to bolster the portfolio.
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take on this division and its growth opportunities. Hint: It's not pharma.
Speaking of growth opportunities...
We all know that the best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson owns shares of Johnson & Johnson. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.